Revenue from operations at Rs. 52,691 mn, up 17% YoY Net Profit at Rs. 10,235 mn, up 30% YoY” ,Zydus Lifesciences Limited Financial Performance for Q3 FY25

Ahmedabad, India : Zydus Lifesciences Ltd. announced its unaudited consolidated financial results for the quarter and nine months ended December 31st, 2024.

Key Financial Highlights 

• Revenue from operations at Rs. 52,691 mn, up 17% over last year.
• Research & Development (R&D) investments for the quarter stood at Rs. 5,031 mn (9.5% of revenues). 
• EBITDA for the quarter was Rs. 13,876 mn, up 26% YoY. EBITDA margin for the quarter stood at 26.3%, which is an improvement of 180 bps on a YoY basis. 
• Net Profit for the quarter was Rs. 10,235 mn, up 30% YoY.
• Capex (organic) for the quarter was Rs. 2,907 mn.

• Revenue from operations at Rs. 167,136 mn, up 19% over last year.
• Research & Development (R&D) investments stood at Rs. 13,756 mn (8.2% of revenues). 
• EBITDA was Rs. 49,330 mn, up 31% YoY. EBITDA margin stood at 29.5%, which is an improvement of 270 bps over the previous year. 
• Net Profit was Rs. 33,546 mn, up 25% YoY.
• Capex (organic) for the nine months was Rs. 8,938 mn.
• Net Debt to Equity ratio as on 31st December, 2024 was -0.14x while Net Debt to EBITDA stood at -0.47x at the end of December, 2024. Net Cash (negative Net Debt) as on 31st December, 2024 was Rs. 30,916 mn. 

Rs. mn	Q3 FY25	Q3 FY24	% Gr. y-o-y	Q2 FY25	% Gr. q-o-q
Revenue from Operations	52,691	45,052	17.0%	52,370	0.6%
EBITDA	13,876	11,024	25.9%	14,614	-5.0%
EBITDA margin (%)	26.3%	24.5%		27.9%
PBT	11,841	9,255	27.9%	12,709	-6.8%
Net Profit	10,235	7,896	29.6%	9,112	12.3%

Rs. mn	9M FY25	9M FY24	% Gr. y-o-y
Revenue from Operations	167,136	1,40,136	19.3%
EBITDA	49,330	37,538	31.4%
EBITDA margin (%)	29.5%	26.8%
PBT	43,547	32,619	33.5%
Net Profit	33,546	26,772	25.3%

Q3 FY25 Business-wise Sales Performance (Consolidated) 

We are pleased with the sustained growth momentum across our key businesses that has driven our Q3 performance. Our robust product portfolio execution in the US, market share gain in focused therapy segments and brands in India, and strategic leveraging of our global portfolio in International Markets position us well for future growth. We are on track to achieve our fiscal year 2025 goal of double-digit growth across our key businesses, coupled with improved profitability. Looking ahead, we are strategically building growth levers to ensure sustained success, with patient centricity and quality at the core of our operations.